Form 11 Drug Import India: CDSCO’s 2026 Proposed Amendment Explained for Pharma Companies

On 23rd June, 2026, the Ministry of Health and Family Welfare published a draft amendment to the Drugs Rules, 1945, proposing to introduce an acknowledgement-based prior intimation system for import of drugs for analytical and non-clinical testing. The draft replaces the existing Form 11 import license requirement for most drugs imported for testing purposes. The draft notification has been placed in the public domain for stakeholder consultation. Objections and suggestions may be submitted until 23rd July, 2026. If finalised as proposed, the amendment will significantly reduce the compliance burden on pharma companies engaged in R&D, quality testing, and dossier preparation for regulated markets.

1. What Is the Current Regime Under the Drugs Rules, 1945?

Under Rules 33 and 34 of the Drugs Rules, 1945, any person seeking to import a drug into India for examination, test, or analysis is required to obtain a prior license in Form 11 from the Central Licensing Authority (CDSCO). Form 11 is an import license specifically for drugs meant for testing and analytical purposes, and is distinct from a commercial import license. The applicant is required to file an application with CDSCO, await regulatory review, and only upon grant of the Form 11 license can the import proceed. Under the current framework, there is no distinction based on the quantity being imported or the purpose of the test. Whether a company is importing a small API sample for a routine analytical test or a larger quantity for a more complex study, the same licensing process applies. This has resulted in delays for companies conducting bioequivalence studies, stability testing, method validation for regulated market filings, and early-stage R&D activities.

2. What Is the Proposed Amendment?

The draft amendment proposes to insert a proviso to Rule 34(1) of the Drugs Rules, 1945, which reads as follows:

“Provided that in case of import of drug for analytical and non-clinical testing (excluding drugs of category of sex hormones, cytotoxic, beta lactam, biologics with live microorganisms and narcotics and psychotropic drugs) an online application in Form 12 to the Central Licencing Authority shall be submitted as prior intimation and the applicant may import such drug based on the acknowledgment of such intimation.”

Under the revised framework, instead of applying for a Form 11 license and waiting for regulatory approval, a company is required to file an online prior intimation in Form 12 with the Central Licensing Authority, receive an acknowledgement, and may then proceed to import without any further regulatory clearance. The amendment also makes consequential changes to Rule 33, which governs what documents must accompany the import, and Rule 35, which deals with cancellation of licenses and appeals. It also updates Form 12 in Schedule A to reflect the dual nature of the document, which can now serve as either a license application or a prior intimation.

Drugs excluded from the simplified system, which still require Form 11:

• Sex hormones
• Cytotoxic drugs
• Beta lactam drugs, such as penicillin-based antibiotics
• Biologics containing live microorganisms
• Narcotics and psychotropic substances

The excluded categories are either high-risk from a handling and safety perspective, require specific containment, or are already subject to additional regulatory controls under separate frameworks. The prior Form 11 licensing requirement continues to apply to these categories.

3. Why Is This Amendment Significant?

A. Alignment with the Existing Domestic Framework

The Ministry of Health and Family Welfare had already amended the New Drugs and Clinical Trials Rules, 2019 in January 2026 to introduce a similar prior intimation system for domestic test licenses. The present amendment extends the same framework to imports, indicating a deliberate policy shift towards a notification-based model for low-risk R&D and testing activities.

B. Alignment with Global Regulatory Practice

The acknowledgement-based system brings India’s import-for-testing framework closer to the approach followed by regulators such as the US FDA and the European Medicines Agency, where research-quantity drug imports for laboratory testing operate on a notification model rather than a prior-approval basis. This alignment is relevant for pharma companies that operate across multiple jurisdictions and are increasingly benchmarking India’s regulatory environment against global standards.

C. Ease of Doing Business in the Pharmaceutical Sector

The amendment is a concrete regulatory measure in support of India’s stated objective of positioning itself as a global pharmaceutical R&D hub. By removing the licensing requirement for low-risk testing imports, it reduces compliance timelines and allows companies to initiate testing and analysis activities without being held up at the import stage. One aspect that practitioners should note: the draft amendment does not define a quantity limit for imports under the prior intimation route. The PIB press release refers to “small quantities,” but the actual draft rule text does not cap the quantity. This is a gap that may be addressed in the final notification, or may be left to CDSCO’s operational guidelines. Companies should watch this closely and consider raising it in their stakeholder feedback before the 23rd July deadline.

4. Impact on the Pharma Industry

A. Startups and Generic Drug Companies

For startups working on new drug formulations, and generic companies conducting bioequivalence studies or stability testing, the amendment removes a material early-stage delay. Importing a drug sample to test an analytical method or run a stability study no longer requires a Form 11 approval. An online prior intimation in Form 12 and the resulting acknowledgement are sufficient to proceed with the import.

B. Finished Product Quality Testing

Pharma companies that manufacture products at overseas facilities often need to import finished drug products into India for quality testing, including packaging integrity checks, drug stability assessments, or investigation of a reported quality issue. Under the current framework, such imports require a Form 11 license even when the purpose is purely analytical. Under the proposed amendment, these imports can proceed on the basis of a prior intimation acknowledgement, enabling faster and more responsive quality investigations.

C. Contract Research Organisations (CROs)

CROs in India frequently need to import drugs from their international clients, including comparator drugs, reference standards, and test samples, to conduct analytical or non-clinical studies. The Form 11 process has often delayed project initiation timelines and, in some cases, led clients to route their testing to overseas labs. This amendment directly reduces that friction, making India-based CROs more competitive for international contracts.

D. Regulated Market Exporters

Companies filing dossiers with the US FDA, EMA, or MHRA need internationally recognised reference standards, typically from USP, EP, or BP pharmacopoeias, for method validation. These reference standards are procured from abroad. The Form 11 requirement has resulted in delays in obtaining them, which in turn affects dossier preparation timelines. With the prior intimation route, companies can access these standards faster, directly accelerating their regulated market filing timelines.

E. Large Pharma and Innovator Companies

For large companies and MNCs, the reduction in administrative overhead is meaningful even where absolute delays are manageable. For early-stage drug discovery work, where teams are evaluating multiple molecules and need rapid access to reference compounds for testing, the ability to import without waiting for a formal license can meaningfully speed up the evaluation cycle.

5. What This Amendment Does NOT Change

• Commercial drug imports are unaffected. The simplified route is strictly for analytical and non-clinical testing. Any import for sale, distribution, or clinical use continues to require the applicable import license.
• Manufacturing and marketing licenses are unaffected. The amendment only touches the import-for-testing pathway.
• The excluded drug categories still require Form 11. Sex hormones, cytotoxics, beta lactams, biologics with live microorganisms, and narcotics and psychotropics continue under the existing licensing requirement.
• CDSCO’s oversight authority remains intact. The prior intimation is submitted to the Central Licensing Authority, and the amendment to Rule 35 makes clear that acknowledgements can be cancelled. The holder of a cancelled acknowledgement may appeal to the Central Government within three months of the date of the order.

6. Key Dates and Next Steps

• Date of Draft Notification: 23rd June, 2026
• Deadline for objections and suggestions: 23rd July, 2026
• Where to submit feedback: Under Secretary (Drugs), Ministry of Health and Family Welfare, Kartavya Bhawan-1, New Delhi – 110001, or via email at drugsdiv-mohfw@gov.in
• Date of effect: To be specified at the time of final gazette publication

Pharma companies, CROs, and industry associations should engage with this draft before the deadline. In particular, the absence of a defined quantity limit, the scope of “analytical and non-clinical testing,” and the operational details of the online Form 12 submission process are areas where industry feedback could meaningfully shape the final rules.

7. Conclusion

The Form 11 import license requirement has been a longstanding compliance burden, particularly for testing and R&D-related imports where the regulatory objective could be served through a lighter-touch mechanism. The proposed amendment addresses this in a measured and well-structured manner. If finalised as proposed, it will reduce delays in drug testing, quality investigations, method validation, and early-stage R&D across the pharma sector. The excluded drug categories are appropriately drawn based on risk. The shift to an online acknowledgement-based system is consistent with the direction that major global drug regulators have taken. The draft is open for stakeholder feedback until 23rd July, 2026. Companies that are affected by this change should engage with the consultation process, particularly on the question of quantity limits and the operational details of the online Form 12 system.

This post is contributed by:

About K&G Techlaw

As a leading healthcare tech law firm in India, we specialise in corporate, commercial and tech law with a special focus on pharmaceutical, healthcare and life sciences. We provide pharmaceutical legal and regulatory compliance support, healthcare legal advisory, and general corporate consultations. As a trusted CDSCO legal consultant India, we assist pharmaceutical and healthcare companies in navigating complex policy shifts, legal amendments and regulatory enforcement matters.

Tags: Drugs and Cosmetics Act, 1940, CDSCO, Regulatory Compliance, Drug Import India, Pharmaceutical R&D, Drug Testing Compliance, Ease of Doing Business Pharma, Schedule H drugs

FAQS: